CFDE Data Portal | Search FBXL14

	Label	Description
	FBXL14 associations Collection (Entity type)	Associations for FBXL14_associations
	FBXL14 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	FBXL14 Gene (Entity type)	ENSG00000171823 - F-box and leucine rich repeat protein 14
	GSE199688 artemisinin 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 cisplatin 7 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE242290 3 V 2 GLUTATHIONE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE228106 3 V 5 PACLITAXEL HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE210476 11 V 4 RUTAECARPINE HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE195663 7 V 1 CISPLATIN HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

FBXL14 associations

Associations for FBXL14_associations

FBXL14 associations.tsv

A file from IDG as part of the Harmonizome project

FBXL14

ENSG00000171823 - F-box and leucine rich repeat protein 14

GSE199688 artemisinin 0 v 1 human dn

A Gene Set from LINCS

GSE195663 cisplatin 7 v 1 human dn

A Gene Set from LINCS

GSE242290 3 V 2 GLUTATHIONE HUMAN DN

A Gene Set from LINCS

GSE228106 3 V 5 PACLITAXEL HUMAN DN

A Gene Set from LINCS

GSE114492 GSE153671 KMT2D inhibition 10 v 7 human dn

A Gene Set from LINCS

GSE210476 11 V 4 RUTAECARPINE HUMAN DN

A Gene Set from LINCS

GSE195663 7 V 1 CISPLATIN HUMAN DN

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.